ClinicalTrials.gg
RecruitingNCT05240976Updated Mar 24, 2026

Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia

A Phase 2 interventional study of NMDAE plus AIFA and NMDAE plus Placebo Cap in Schizophrenia, sponsored by China Medical University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by China Medical University Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Schizophrenia by China Medical University Hospital — 8 open to participants now, 8 under way, none of them phase 3. Schizophrenia · China Medical University Hospital.

Planned enrollment
5th of 14
80 · median 60
Started
2022
the only one that year
Phase 2
14 of 15
8 open now
Registered
12th of 15
by date

Among the 15 studies in Schizophrenia by China Medical University Hospital, this one is the 5th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2022, is one of 14 in phase 2, and was the 12th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

8 of the 15 studies in Schizophrenia by China Medical University Hospital are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Schizophrenia by China Medical University Hospital, or all of them as a file.
02

Study summary

Previous study found that some NMDA-enhancing agent was able to augment efficacy of clozapine for clinical symptoms but not cognitive function in the treatment of ultra-resistant schizophrenia. In addition, several drugs with anti-inflammatory properties have been tested in clinical trials for the treatment of schizophrenia. Whether a drug with anti-inflammatory property can strengthen the efficacy of an NMDA-enhancer (NMDAE) in the treatment of ultra-resistant schizophrenia remains unknown.

Read the detailed description

Several lines of evidence suggest that both NMDA and inflammatory hypotheses have been implicated in schizophrenia. Previous study found that some NMDA-enhancing agent was able to augment efficacy of clozapine for clinical symptoms but not cognitive function in the treatment of ultra-resistant schizophrenia. In addition, several drugs with anti-inflammatory properties have been tested in clinical trials for the treatment of schizophrenia. Whether a drug with anti-inflammatory property can strengthen the efficacy of an NMDA-enhancer (NMDAE) in the treatment of ultra-resistant schizophrenia remains unknown.

Therefore, this study aims to compare NMDAE plus a drug with anti-inflammatory property and NMDAE plus placebo in the treatment of ultra-resistant schizophrenia. The subjects are the patients with ultra-resistant schizophrenia who have responded poorly to clozapine treatment. They keep their original clozapine treatment and are randomly, double-blindly assigned into two treatment groups for 12 weeks: (1) NMDAE plus Anti-inflammatory Agent (AIFA), or (2) NMDAE plus placebo. Cognitive functions are assessed at baseline and at endpoint of treatment by a battery of tests. Clinical performances and side effects are measured at weeks 0, 2, 4, 6, 9, and 12. The efficacies of NMDAE plus AIFA and NMDAE plus placebo will be compared.

Chi-square (or Fisher's exact test) will be used to compare differences of categorical variables and t-test (or Mann-Whitney test if the distribution is not normal) for continuous variables between treatment groups. Mean changes from baseline in repeated-measure assessments will be assessed using the generalized estimating equation (GEE) for both primary and secondary outcomes . All p values for clinical measures will be based on two-tailed tests with a significance level of 0.05.

03

Conditions studied

  • Schizophrenia

Keywords

  • Ultra-resistant schizophrenia
  • NMDA
  • Inflammation
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a (American Psychiatric Association) diagnosis of schizophrenia
  • Are treatment-resistant to standard treatments of at least two specific antipsychotics before clozapine treatment
  • Are receiving adequate trials of clozapine for more than 12 weeks but without satisfactory response
  • PANSS total score ≥ 70; SANS total score ≥ 40
  • Have sufficient education to communicate effectively and are capable of completing the assessments of the study
  • Agree to participate in the study and provide

Exclusion criteria

Exclusion Criteria:

  • diagnosis of intellectual disability or substance (including alcohol) use disorder
  • History of epilepsy, head trauma, or serious medical or central nervous system diseases (other than schizophrenia) which may interfere with the study
  • laboratory screening tests (including blood routine, biochemical tests)
  • Pregnancy or lactation
  • Inability to follow protocol
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    NMDAE plus Anti-inflammatory Agent (AIFA)

    An NMDA enhancer plus a drug with anti-inflammatory property

    Drug: NMDAE plus AIFA

  • Placebo comparator
    NMDAE plus Placebo

    An NMDA enhancer plus Placebo

    Drug: NMDAE plus Placebo Cap

Interventions

  • DrugNMDAE plus AIFA

    Use of an NMDA enhancer plus a drug with anti-inflammatory property for the treatment of ultra-resistant schizophrenia.

  • DrugNMDAE plus Placebo Cap

    Use of an NMDA enhancer plus placebo as a comparator

06

What researchers measure

Primary outcomes

  1. Change of cognitive function

    The measure is the composite from multiple measures. All tests have no unit. For the domain (a. and c.) with more than one test, a composite T score will be calculated by standardizing the average of each T score. Furthermore, a global composite score (for all seven domains) and a neurocognitive composite score (for the first 6 domains) will be also calculated by standardizing the average of the T score of each domain (Lane HY et al, JAMA Psychiatry 2013). Ten tests for assessing 7 cognitive domains: 1. speed of processing (assessed by Category Fluency, Trail Marking A, WAIS-III Digit Symbol-Coding); 2. sustained attention (Continuous Performance Test); 3. working memory: verbal (digit span) and nonverbal (spatial span); 4. verbal learning and memory (WMS-III, word listing); 5. visual learning and memory (WMS-III, visual reproduction); 6. reasoning and problem solving (WISC-III, Maze); 7. social cognition (MSCEIT Version 2)

    Time frame: Week 0, 12

Secondary outcomes

  1. Change of Positive and Negative Syndrome Scale (PANSS)

    Assessment of overall symptoms. Minimum value: 30, maximum value:210, the higher scores mean a worse outcome. As shown in "Detailed Description", "mean changes from baseline in repeated-measure assessments will be assessed using the generalized estimating equation (GEE) for both primary and secondary outcomes. That is, GEE is used for analyzing the changes from baseline in repeated-measure assessments by a single analysis (but not multiple analyses).

    Time frame: week 0, 2, 4, 6, 9, 12

  2. Change of scale for the Assessment of Negative Symptoms (SANS) total score

    Assessment of negative symptoms. Minimum value: 0, maximum value:100, the higher scores mean a worse outcome.

    Time frame: week 0, 2, 4, 6, 9, 12

  3. Chang of positive subscale of PANSS

    Assessment of positive symptoms. Minimum value: 7, maximum value:49, the higher scores mean a worse outcome.

    Time frame: week 0, 2, 4, 6, 9, 12

  4. Change of negative subscale of PANSS

    Assessment of negative symptoms. Minimum value: 7, maximum value:49, the higher scores mean a worse outcome.

    Time frame: week 0, 2, 4, 6, 9, 12

  5. Change of general Psychopathology subscale of PANSS

    Assessment of general psychopathology. Minimum value: 16, maximum value:112, the higher scores mean a worse outcome

    Time frame: week 0, 2, 4, 6, 9, 12

  6. Change of clinical Global Impression

    Assessment of general impression. Minimum value: 1, maximum value:7, the higher scores mean a worse outcome.

    Time frame: week 0, 2, 4, 6, 9, 12

  7. Change of global Assessment of Functioning

    Assessment of social, occupational, and psychological function. Minimum value: 1, maximum value:100, the higher scores mean better function.

    Time frame: week 0, 2, 4, 6, 9, 12

  8. Change of hamilton Rating Scale for Depression

    Assessment of depressive symptoms. Minimum value: 0, maximum value:52, the higher scores mean a worse outcome.

    Time frame: week 0, 2, 4, 6, 9, 12

  9. Change of quality of Life Scale

    Assessment of life quality. Minimum value: 0, maximum value:126, the higher scores mean a better outcome.

    Time frame: week 0, 2, 4, 6, 9, 12

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Feb 2027, 60 months after the start.

Of 44 non-industry phase 2 interventional studies under Schizophrenia, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 73. This study's planned 60 months is above that.

Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2022
First posted
Feb 15, 2022
StartActual
Feb 23, 2022
Primary completionEst.
Feb 2027
CompletionEst.
Mar 2027
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05240976
Responsible party
Sponsor
First posted
Feb 15, 2022
Start date
Feb 23, 2022
Primary completion
Feb 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Mar 24, 2026

Study contacts

Hsien-Yuan Lane, M.D., Ph.D
Contact
hylane@gmail.com
886 4 22052121 ext. 1855

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion